Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00218556 · ClinicalTrials.gov registry record · NA

Preventing Depression in Methadone Maintenance Patients Receiving Hepatitis C Treatment - 1

A NA study of Hepatitis C and Depressive Disorder, Major, sponsored by National Institute on Drug Abuse (NIDA).

Completed
Registry status
NA
Development phase
42
Enrollment target
1
Study location

NCT00218556: Completed NA study of Hepatitis C and Depressive Disorder, Major, sponsored by National Institute on Drug Abuse (NIDA).

NCT00218556 is a NA study of Hepatitis C and Depressive Disorder, Major that has completed, run by National Institute on Drug Abuse (NIDA). The registered enrollment target is 42 participants, below the 1,890-participant average among 106 other Hepatitis C trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00218556, a NA study of Hepatitis C and Depressive Disorder, Major, has completed, sponsored by National Institute on Drug Abuse (NIDA).

COMPLETED
Registry status
NA
Development phase
42 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study is develop and test a cognitive-behavioral intervention to prevent depression in methadone maintenance patients receiving medical treatment for hepatitis C.

Interventions

  • BEHAVIORAL Cognitive behavioral treatment for depression

Study Locations (1)

Rhode Island

  • Rhode Island Hospital - Providence

Trial Details

FieldValue
Enrollment Target 42 participants
Start Date 2004-01
Est. Completion 2008-06
Phase NA

What the finished NCT00218556 record still lists

NCT00218556 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 42 participants, a relatively small participant target, below the 1,890-participant average among 106 other Hepatitis C trials with a reported enrollment target (98% lower).

The record links to 2 conditions, with Hepatitis C appearing as the primary indexed condition, and to 1 intervention - of which Cognitive behavioral treatment for depression is the first listed.

NCT00218556 reports a single indexed study location in Rhode Island.

Frequently Asked Questions

What is clinical trial NCT00218556 about?

NCT00218556 is a clinical study titled "Preventing Depression in Methadone Maintenance Patients Receiving Hepatitis C Treatment - 1". The purpose of this study is develop and test a cognitive-behavioral intervention to prevent depression in methadone maintenance patients receiving medical treatment for hepatitis C.

What is the current status of trial NCT00218556?

This trial is currently completed. It is a NA study. The enrollment target is 42 participants. The study started on 2004-01. Estimated completion is 2008-06.

What conditions does trial NCT00218556 study?

This clinical trial studies the following conditions: Hepatitis C, Depressive Disorder, Major.

What interventions are being tested in trial NCT00218556?

The interventions under investigation include: Cognitive behavioral treatment for depression (BEHAVIORAL).

Who is sponsoring clinical trial NCT00218556?

This trial is sponsored by National Institute on Drug Abuse (NIDA), which has 335 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00218556 being conducted?

This trial has 1 study location across Rhode Island. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Hepatitis C

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT00218556's enrollment target sits among peer trials

42 78th of 106 higher than 29 of 106 other Hepatitis C trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Hepatitis C trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02852213 · 42 participants · Phase 1

    A Single-Stage, Adaptive, Open-label, Dose Escalation Safety and Efficacy Study of AADC Deficiency in Pediatric Patients

  • NCT03136146 · 42 participants · Phase 2

    Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Burkitt Lymphoma/Leukemia, or Double-Hit Lymphoma/Leukemia

  • NCT03178149 · 42 participants · Phase 1

    A Study of the Safety and Tolerability of ASP7317 in Senior Adults Who Are Losing Their Clear, Sharp Central Vision Due to Geographic Atrophy Secondary to Dry Age-related Macular Degeneration

  • NCT03663530 · 42 participants · NA

    Circadian Misalignment and Energy Balance

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00218556, the US trial registry maintained by the National Library of Medicine. NCT00218556 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.